home

Apricus Reports Top-Line Phase 2b Data for Fispemifene in Symptomatic Secondary Hypogonadism

TrendYAHOO2016-03-29 09:16 Read   109

Fispemifene Failed to Achieve Statistical Significance in Key Clinical Benefit Endpoints Despite Increase in Testosterone Levels

Endo Provides Statement Regarding Expected FDA Approval Of Generic Voltaren® Gel Product

TrendEndo 2016-03-28 09:13 Read   169

Endo International plc (NASDAQ: ENDP) (TSX: ENL) today provided a statement and a Frequently Asked Questions (FAQs) document regarding the expected approval by the U.S. Food and Drug Administration of a competitor's generic version of Voltaren® Gel (diclofenac sodium topical gel) 1%.

Bayer looks to protect blockbuster Eylea franchise with $130M Regeneron pact

TrendBayer2016-03-25 09:42 Read   131

Bayer is gambling up to $130 million to lay claim to half the ex-U.S. profits that may lie ahead for one of Regeneron's ($REGN) next-gen combination eye drugs, a successor to their blockbuster Eylea franchise. 

Envisia Gets $16.5M More to Back Extended-Release Eye Drugs

TrendXconomy2016-03-24 14:17 Read   119

Investors in Envisia Therapeutics are pumping $16.5 million more into the eye drug developer to carry the company’s lead candidate, a potential glaucoma treatment, through mid-stage clinical trials.

Valneva launches a Commercial Operation in the UK

TrendFirstword2016-03-24 14:11 Read   120

Valneva, a specialist vaccines company with offices in France, Austria, Sweden, Canada and the US, has now established a Commercial Operation in the UK. The company already has a manufacturing site in Livingston, Scotland.

Analyst slashes Entresto sales forecast in half as skeptical heart docs hobble uptake

TrendFiercepharma2016-03-24 13:52 Read   168

When Novartis ($NVS) execs predicted big things for their Entresto launch, they didn't promise it would happen overnight.

Cellceutix Pipeline Continues to Hit Milestone After Milestone

TrendCellceutix2016-03-24 11:10 Read   122

Cellceutix Corp. (CTIX:OTCMKTS), a small-cap biotech company focused on developing novel compounds for a range of applications, has released a flurry of announcements over the past five weeks as several of its pipeline drugs cleared regulatory hurdles and readied for their next milestones. The series of press releases on three different Cellceutix experimental drugs put a charge in the stock, sending it upward in a matter of a few days by more than 57% to a high of $1.81/share on Tuesday, March 21.

Amgen and UCB's romosozumab hits goals in male osteoporosis

TrendAmgen2016-03-24 10:17 Read   175

A phase III study of Amgen and UCB's romosozumab in men with osteoporosis has met its objectives, adding to earlier positive data in post-menopausal women.

Bristol-Myers bags biotech upstart Padlock in $600M autoimmune deal

TrendBristol-Myers Squibb2016-03-24 09:46 Read   143

Bristol-Myers Squibb ($BMY) has struck a $600 million deal to buy out the biotech startup Padlock Therapeutics and its autoimmune R&D platform.

BioMarin Heads to FDA With Mixed Data For Rare Disease Drug

TrendXconomy2016-03-23 13:05 Read   123

BioMarin Pharmaceutical had a setback in January when a gamble it had made on a Duchenne muscular dystrophy drug failed.

NICE backs Novartis' Entresto for heart failure

TrendPMLIVE2016-03-23 12:34 Read   95

The National Institute for Health and Care Excellence (NICE) has confirmed that Novartis' Entresto will be covered by the NHS for some patients with chronic heart failure (CHF).

Will Eli Lilly's 11th-hour regulatory gambit salvage or sink its Alzheimer's drug?

TrendFIERCE BIOTECH2016-03-23 10:58 Read   113

Eli Lilly ($LLY) didn't just surprise investors with its sudden about-face last week on its long-running Phase III program for the Alzheimer's drug solanezumab.